Leerink Partnrs Brokers Increase Earnings Estimates for HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities researchers at Leerink Partnrs raised their Q1 2025 EPS estimates for shares of Hims & Hers Health in a note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.11 per share for the quarter, up from their prior forecast of $0.10. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q2 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.17 EPS, FY2025 earnings at $0.56 EPS, FY2026 earnings at $0.75 EPS and FY2027 earnings at $1.15 EPS.

Several other research firms have also recently issued reports on HIMS. Piper Sandler upped their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday. TD Cowen restated a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Finally, BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $35.71.

Hims & Hers Health Stock Performance

HIMS opened at $41.30 on Thursday. The stock has a market capitalization of $9.02 billion, a P/E ratio of 93.85 and a beta of 1.35. The company’s 50-day simple moving average is $36.19 and its two-hundred day simple moving average is $26.46. Hims & Hers Health has a 52-week low of $11.20 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the stock. Main Management ETF Advisors LLC purchased a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $672,000. Robeco Institutional Asset Management B.V. purchased a new position in shares of Hims & Hers Health in the third quarter valued at $604,000. Royce & Associates LP grew its holdings in shares of Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after purchasing an additional 49,500 shares in the last quarter. Versor Investments LP purchased a new position in shares of Hims & Hers Health in the third quarter valued at $634,000. Finally, International Assets Investment Management LLC purchased a new position in shares of Hims & Hers Health in the third quarter valued at $6,790,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at $9,319,952.14. This trade represents a 8.20 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the sale, the insider now directly owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,097,578 shares of company stock worth $38,080,320. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.